Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record.

Muscarinic receptors in the bladder: from basic research to therapeutics

Open access
Hegde, Sharath S. · 2006 · British Journal of Pharmacology

Abstract

Muscarinic receptor antagonists (antimuscarinics) serve as the cornerstone in the pharmacological management of overactive bladder (OAB) by relieving the symptoms of urgency, frequency and incontinence. These drugs operate primarily by antagonizing post‐junctional excitatory muscarinic receptors (M 2/M 3) in the detrusor. The combination of pharmacological and gene knockout studies has greatly advanced our understanding of the functional role of muscarinic receptors in the bladder. M 3 receptors produce direct smooth muscle contraction by a mechanism that relies on entry of extracellular calcium through L‐type channels and activation of a rho kinase. M 2 receptors, which predominate in number, appear to facilitate M 3‐mediated contractions. M 2 receptors can also produce bladder contractions indirectly by reversing cAMP‐dependent β‐adrenoceptor‐mediated relaxation, although the physiological role of β‐adrenoceptors in detrusor relaxation is controversial. Emerging evidence suggests that muscarinic receptors in the urothelium/suburothelium can modulate the release of certain factors, which in turn may affect bladder function at the efferent or afferent axis. Currently, oxybutynin, tolterodine, darifenacin, solifenacin and trospium are the five major antimuscarinics approved for the treatment of OAB. Comparative clinical studies have shown that oxybutynin and solifenacin may be marginally more effective than tolterodine, although the latter seems to be better tolerated. Pharmacokinetic–pharmacodynamic analyses using plasma concentrations of ‘total drug’ indicate that, at therapeutic doses, the clinical efficacy of darifenacin and solifenacin may be driven primarily by selective M 3 receptor occupation, whereas the pharmacodynamic effects of pan‐selective molecules (such as tolterodine, trospium) may potentially involve multiple receptors, including M 2 and M 3. Furthermore, high M 3 receptor occupation is the likely explanation for the greater propensity of darifenacin and oxybutynin to cause dry mouth and/or constipation. Although the recently introduced drugs represent a significant improvement over older drugs, especially with respect to the convenience of dosing schedule, their overall efficacy and tolerability profile is still less than optimal and patient persistence with therapy is low. Recent advances in basic research have not yet offered a clear discovery path for improving the therapeutic index of antimuscarinic molecules. There is still an unmet need for an antimuscarinic medicine with superior clinical effectiveness that can translate into better persistence on therapy. British Journal of Pharmacology(2006)147, S80–S87. doi:10.1038/sj.bjp.0706560

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0706560

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 232

Metadata

Authors
Hegde, S. S.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2006-02
Volume
147
Issue
S2
Pages
S80-7
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2072797090
Cited by
232
References
0
FWCI
25.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscarinic receptors in the bladder: from basic research to therapeutics. https://app.cochat.ai/papers/10.1038/sj.bjp.0706560
The paper
Hegde, S. S. (2006). Muscarinic receptors in the bladder: from basic research to therapeutics. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0706560

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.